Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosa
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #genetherapy--Eyevensys receives FDA Orphan Drug Designation for EYS611 for treatment of retinitis pigmentosa.